← ANALYST RATINGS · TIPRANKS
Tonix Pharma (TNXP): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $27.00, the highest $27.00, the lowest $27.00. The average is +347.0% from the last price of $6.04.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $6.00−7.7% | Hold | −0.7% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.50 → $6.00−7.7% | Hold | −0.7% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $6.00−7.7% | Hold | −0.7% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.50 → $5.50−15.4% | Sell | −8.9% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.50 → $6.00−7.7% | Hold | −0.7% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $6.00−7.7% | Hold | −0.7% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| James Molloy★★★★★★★★★★#12352 · hits 25% · avg −19.8% | Alliance Global Partners | $65.00 | Buy | +976.2% | Reiterated | 28.09.26on TipRanks 09:05 | +1.1%next day −2.3% · 5 days −19.7% | ↗ |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | $22.00 | Buy | +264.2% | Reiterated | 10.08.26on TipRanks Aug 11 02:35 | +4.7%next day −1.7% · 5 days +0.6% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | $26.00 → $27.00+3.8% | Buy | +347.0% | Reiterated | 10.08.26on TipRanks 14:00 | +4.7%next day −1.7% · 5 days +0.6% | ↗ |
| Robert LeBoyer★★★★★★★★★★#12335 · hits 27% · avg −14.2% | Noble Financial | $70.00 → $37.00−47.1% | Buy | +512.6% | Reiterated | 16.03.26on TipRanks 09:10 | +1.4%next day +10.1% · 5 days +20.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Tonix Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.00 at a price of $9.74 (+290.1%); now: $38.00 at $6.04 (+529.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-2.45 (from $-2.63 to $-2.15). Last quarter: $-2.44.
Sales
Next quarter’s sales estimate — $16M (from $15M to $19M). Last quarter: $14M.
Best top-analyst consensus in the sector · Healthcare
About Tonix Pharma
- CEO: Seth Lederman
- Employees: 142
- 200 Connell Drive, Berkeley Heights, NJ, 07928, US
- www.tonixpharma.com
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its
Data from the stock’s TipRanks forecast page, read 107 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗